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Abstract
Background: This study aimed to establish the profile and the evolution of an early Rheumatoid arthritis (RA)
cohort in the Moroccan population and also to search possible predictor factors of structural progression.
Methods: Patients with early RA (< 12 months) were enrolled in a 2-year follow-up study. Clinical, biological,
immunogenetic, and radiographical data were analyzed at study entry and at 24 months. Presence of radiographic
progression was retained when the total score was superior to the smallest detectable difference (SDD) calculated
to be 5.4 according the Sharp/van der Heijde (SVDH) method.
Results: Fifty one patients (88.8% women, mean age of 46.9 [ 24-72 ] ± 10.8 years, mean disease duration of
24 [ 6-48 ] ± 13.9 weeks) were enrolled in this study. 68.6% were illiterate and 19.6% reported at least one
comorbid condition. The mean delay in referral for specialist care was 140 [ 7-420 ] ± 43 days.
Thirteen patients (62.5%) were IgM or IgA RF positive. HLA-DRB1*01 and DRB1*04 alleles were present respectively
in 11.8% and 45.1% of patients.
At baseline, 35.3% patients were taking corticosteroids and 7.8% were under conventional DMARDs.
At 24 months, 77.2% received a median dose of 5 mg/day of prednisone. Methotrexate (MTX) was the most
frequently prescribed DMARD, being taken by 65.2% of patients. 13.6% of patients had stopped their DMARD
because of socioeconomic difficulties.
Comparison of clinical and biologic parameters between baseline and 24 months thereafter revealed a significant
global improvement of the disease status including morning stiffness, pain score, swollen joint count, DAS 28 and
HAQ scores, ESR and CRP.
Sixteen patients (34.8%) were in remission at 2 years versus no patients at baseline; P < 0.001.
Forteen patients (27.5%) had at least one erosion at baseline. Radiographic progression occurred in 33.3% of
patients and was associated in univariate analysis to swollen joint count (p = 0.03), total SVDH score (P = 0.04) and
joint space narrowing score (P = 0.03). No independent factors of radiographic progression were shown by logistic
regression.
Conclusions: These study reports, provided for the first time in Morocco, a developing African country, a large
amount of information concerning the profile and the course of early RA.
Patients who were receiving, for most of them, Methotrexate in monotherapy and low doses of corticosteroids,
showed an improvement of all clinic and biologic disease parameters. Moreover, DAS remission was obtained in
one third of patients and two thirds of the cohort had no radiographic progression at 2 years. No predictor factors
of radiographic progression were found out.
These results should be confirmed or not by a large unbiased RA cohort which will give more relevant information
about early RA characteristics and its course and will constitute a major keystone of its management.
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Rheumatoid arthritis (RA) is the most common inflam-
matory chronic disease of the joints. It is characterized
by disease activity and bone destruction resulting in
joint destruction, functional impairment, and increased
mortality [1-3]. In Morocco, RA has a major socioeco-
nomic impact [4]. The low socioeconomic status of
many patients and the inadequate social welfare and
health insurance systems contribute to weight of this
burden [4].
Early recognition of RA and intervention appear to be
keys to optimal management of this chronic disabling
disease [5]. There is a lack of research on early RA in
Morocco. The purpose of this study is to establish the
profile and the course of an early RA cohort between
baseline and 2 years later. We would like also to deter-
mine in this prospective study if there are any possible
predictor factors of structural progression.
Methods
Patients
A cohort of consecutive adults patients with RA aged
between 18 and 70 years who suffered from the disease for
less than 1 year was recruited in this study between Janu-
ary 2005 and December 2006. RA patients were diagnosed
by rheumatologists with reference to the American Col-
lege of Rheumatology (ACR) classification criteria [6].
Patients were followed by their rheumatologist and
addressed for assessment as outpatients in El Ayachi hos-
pital (public structure and referral hospital of Rheumatol-
ogy in Morocco where hospitalizations and outpatient
clinics are accessible for patients originary from different
regions of our country) at baseline and 2 years thereafter.
The choice of treatment in this cohort according to the
protocol was left to the discretion of the treating physi-
cians. All patients agreed to enrollment in a 2-year follow-
up study and signed written informed consent. The study
was approved by the ethics review.
Patients’ features and disease characteristics
Patients’ features and disease characteristics were assessed
at baseline and 2 years after. Thus, the following para-
meters were collected at study entry: age, sex, educational
level, rural or urban provenance, adherence to a health
insurance system, comorbidity (other chronic diseases
requiring long-term medical care), disease duration,
patient’s assessment of pain (on a visual analog scale),
number of swollen and tender joints (both by 28 joint
count), extra-articular manifestations, functional status
evaluated by the Moroccan adapted version of Health
Assessment Questionnaire (HAQ) [7], erythrocyte sedi-
mentation rate (ESR), C reactive protein (CRP) level, IgM
or IgA rheumatoid factor (RF) positivity (20 IU/ml and
7 units/ml, respectively), Anti-citrullinated protein/peptide
antibodies (ACPA) positivity using second generation anti-
CCP assay (CCP2) of ELISA and HLA typing of class II
(-DR and 15 DQ) tested by ‘’Polymerase chain reaction
sequence specific primers’’ (PCR-SSP).
We assessed patient disease activity at baseline and 2
years thereafter using the 28 joint disease activity score
(DAS 28). Remission was defined by a DAS 28 score
< 2.6 [8].
At 24 months, the clinical assessment included num-
ber of swollen and tender joints (both by 28 joint count)
and also DAS 28, HAQ and pain scores. The laboratory
investigations included ESR and CRP dosages.
Concerning treatments, we recorded at baseline and at
24 months doses of oral corticosteroids and type of
DMARDs received by patients.
Radiographs of the hands and feet were obtained at
baseline and 2 years thereafter. Structural damage was
assessed by counting the number of erosions and grad-
ing the joint space narrowing (JSN) according to the
Sharp and van der Heijde method [9].
All radiographs were scored separately by two experi-
enced assessors, who were unaware of the clinical data of
the patients. The x ray pictures were read in their chrono-
logical sequence. Each observer performed every measure-
ment twice. Intra-observer reliability was evaluated by
linear regression between the outputs of the first and sec-
ond measurements, and intra-observer error was calcu-
lated as the absolute difference between measurements
[10]. Radiographic inter-observer agreement was (ICC) =
0.89 and intra-observer ICC varied between 0.93 and 0.92.
Those findings indicated good intra-observer and inter-
observer reliability and are in line with literature [11].
The smallest detectable difference (SDD), defined as that
number greater than the measurement error of progres-
sion, was determined using the metric 95% limits of agree-
ment method of Bland and Altman [10,12]. Using this
method, SDD was calculated to be 5.4. Thus, presence of
radiographic progression was retained when the total
score was superior to the SDD leading to a simple division
into radiological progression and no progression.
Statistics
Descriptive statistics of the patients and disease character-
istics were calculated. Student’s t test and the chi-squared
test were used as appropriate to compare the evolution of
clinic, biologic and radiographic parameters between out-
set and 24 months thereafter. Outcome variables were
dichotomized into qualitative variables: presence or
absence of radiologic progression, presence or absence of
remission.
Univariate analysis tested most of the clinical, biologic,
immunologic and genetic factors that were previously
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in RA.
Multivariate logistic regression analyses were also con-
ducted. A statistical significance level of P < 0.05 was used
in all statistical tests performed. Analyses were performed
using the SPSS program (version 13.0; SPSS Inc., Chicago,
IL, USA).
Results
Patients’ and disease’ features at baseline
Fifty one patients (45 women, 6 men) were enrolled in this
study. Six patients (1 patient died, 5 refused further fol-
low-up) were lost to follow-up at 2 years. Data on 45
patients were thus available for analysis 2 years after their
inclusion in the study.
Of all participants, 68.6% were illiterate and only 3.9%
had been to high school. Five patients (9.8%) adhered to a
health insurance system. Overall, 10 cases (19.6%)
reported at least one comorbid condition (arterial hyper-
tension (5.8%) hypercholesterolemia (3.9%), diabetes mel-
littus (5.8%) and hypothyroïditis (3.9%)).
At baseline, the mean age of patients and the mean dis-
ease duration were respectively 46.9 [24-72] ± 10.8 years
and 24 [6-48] ± 13.9 weeks. The mean delay in referral for
specialist care was 140 [7-420] ± 43 days. Thirteen patients
(62.5%) were IgM or IgA RF positive. Positivity of ACPA
was noted in 56.6% of patients.
HLA-DRB1*01 and DRB1*04 alleles were present
respectively in 11.8% and 45.1% of patients. At baseline,
DAS 28 and HAQ scores were respectively 6.9 [3.7- 9.9] ±
1.3 and 2.2 [0.7-3] ± 0.6.
At study entry, eighteen patients (35.3%) were already
taking corticosteroids and 4 patients (7.8%) were under
conventional DMARDs (Methotrexate (n = 1) and Metho-
trexate associated to Chloroquine (n = 3)).
At 24 months assessment, thirty four patients (77.2%)
received a low dose of prednisone with a median dosage of
5 mg/day. During the study, all patients were receiving
conventional DMARDs in monotherapy. Methotrexate
(MTX) was the most frequently prescribed DMARD,
b e i n gt a k e na tad o s eo f1 5m go n c eaw e e kb y6 5 . 2 %o f
patients and followed by Sulfasalazine and Chloroquine
(10.8% for each of them). At the 24 months assessment,
6 patients (13.6%) had stopped the DMARD for socioeco-
nomic difficulties. None of patients received combination
therapy or biologic agents.
Table 1 shows the patients’ and disease’ characteristics
at baseline.
Early RA evolution between baseline and at 24 months
Table 2 shows a comparison of clinical and biologic
parameters of the RA between inclusion and 24 months
later. These results revealed a significant global improve-
ment of the disease status including morning stiffness,
pain score, swollen joint count, DAS 28 and HAQ
scores, ESR and CRP.
Disease activity and remission
In RA patients, the mean DAS 28 decreased significantly
from an initial mean score of 6.9 [3.7-9.9] ± 1.3 in range
of high disease activity to 3.7 [0.5- 9.2] ± 1.9 into the
range of moderate disease activity; P < 0.001. Sixty
patients (34.8%) were in remission versus no patients at
baseline; P < 0.001.
Structural damage and radiological progression
Forteen patients (27.5%) had at least one erosion at
baseline. At 2 years, the median of total SVDH, ero-
sions, and joint space narrowing scores increased
Table 1 Patient and disease characteristics at baseline
Baseline variable Value
Sex, % women 88.2
Age, years 46.9 [24-72] ± 10.8
Provenance, % urban/rural 74.5/25.5
Education level
Analphabet, % 68.6
High level school, % 3.9
Comorbidity, % 18.6
Disease duration, weeks 24 [6-48] ± 13.9
Referral to specialist delay, days 140 [7-420] ± 100
Stiffness duration, mn 138 [15-360] ± 76
Extraarticular manifestations, % 1.8
ESR, mm/hour 57.2 [5-115] ± 25.8
CRP, mg/liter 26.8 [0-96] ± 22
RF positivity, % 62.5
Antibody positivity, % 7.8
ACPA positivity, % 56.6
HLA-DRB1*04, % 45.1
HLA-DRB1*01, % 11.8
Patient global assessment (0-10) 3.4 [0-8] ± 1.6
Physician global assessment (0-10) 6.2 [1-10] ± 1.7
Patient pain assessment (0-10) 6.6 [1-10] ± 1.8
Tender joint count (0-28) 20.4 [8-48] ± 10.1
Swollen joint count (0-28) 9.6 ± 6.5
HAQ (0-3) 2.2 [0.7-3] ± 0.6
Presence at least of one erosion, % 27.5
Total SVDH score 1 (0-5)*
Erosion score 0 (0-1)*
Joint space narrowing score 1 (0-3)*
Treatment received
Corticosteroids, % 35.3
DMARD, % 7.8
Values are presented as mean or percentage.
* Values are presented as median and quartiles.
RA: Rheumatoid Arthritis: RF: Rheumatoid Factor; HAQ: Health Assessment
Questionnaire; DAS 28: Disease Activity Score; ESR: erythrocyte sedimentation
rate; CRP: C-reactive protein; DMARDs: Disease-Modifying Anti-Rheumatic Drugs.
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1) to 0(0-2); P < 0.001, and from 1(0-3) to 3(1-8) ); P <
0.001; (Table 3).
In this inception cohort of 45 patients with early RA,
33.3% showed progressive joint damage over 2 years
(their total score was superior to the SDD).
Table 4 shows a comparison of outset parameters
between the two groups according to the presence of
radiological progression at the 2 year- follow-up. In this
univariate analysis, radiological progression risk was sig-
nificantly associated with swollen joint count (P= 0.03),
total SVDH score (P = 0.04) and joint space narrowing
score (P = 0.03). No association was noted for any other
variables. Logistic regression showed that there were no
independent factors of radiographic progression.
Comparing clinical and biologic characteristics of pro-
gressor and non-progressor patients at the 24 months,
showed no significant (NS) differences in swollen joint
(2.8 vs 1.1; P:N S ) ,t e n d e rj o i n t s( 1 1 . 5v s6 . 5 ;P:N S ) ,
ESR (31.2 vs 27.8; P: NS), HAQ (0.7 vs 0.6; P: NS), DAS
28(3.9 vs 3.6; P: NS), and patient pain assessment (3.1 vs
2.3; P: NS).
Discussion
This prospective study constitutes a real-life design and
provides, for the first time in Morocco and to our
knowledge in Africa, the profile of early RA in a devel-
oping African country. It shows also that there are no
predictor factors of radiographic progression after
2 years of follow-up.
The age onset of RA in Morocco has been reported in
a previous retrospective study to be lower than in
western countries [13]. In the same way, recent data on
the profile of patients with RA in 8 clinics in North
Africa (Morocco and Egypt) in the QUEST-RA (Quanti-
tative Standard Monitoring of Patients with RA) data-
base, shows that patients in North Africa are younger
than patients in other countries [14]. Then, our findings
of similarity of with RA age onset in western countries
should be taken with caution and may not be extended
to the Moroccan population.
The optimal approach to early RA management
requires early referral of patients with arthritis to specia-
lists and early diagnosis of the disease using mainly clini-
cal and serological investigations [15]. In our study
population, referral to specialists was delayed since it
took nearly 20 weeks. Therefore, more awareness of the
generalists is required to promote early referral to a spe-
cialist in order to guarantee the patient’s early diagnosis
and therapeutic intervention. This early diagnosis chal-
lenge remains greater for developing countries where RA
management is still not considered as a public health
priority even if it constitutes an enormous socioeconomic
burden [4,16].
ACPA has acquired for many years a great interest in
early RA diagnosis. It’s to be noted that our ACPA percen-
tage result was similar to that reported by Meyer and al in
their cohort [17]. Regarding the genetic concern, associa-
tion with Human Leukocyte Antigen (HLA)-DRB alleles,
implicated in the aetiopathogenesis of Rheumatoid Arthri-
tis (RA), is found to be different in various ethnic groups
[18]. In the Moroccan population, there is only one study
which focused on evaluating the distribution of class I and
class II HLA genes. In this controlled data, Atouf et al
Table 2 Comparison of clinical and biologic parameters of the early RA between baseline and 2 years
Parameters Baseline 2 years of follow-up P
Morning stiffness 120 (60-180)* 10(0-75)* < 0,001
Patient pain assessment 70 (50-80) * 20(0-50)* < 0,001
Swollen joint count 9 (4-14) * 0(0-2)* < 0,001
DAS 28 6,9 [3.7-9.9] ± 1.3 3,7 [0.5-9.2] ± 1.9 < 0,001
HAQ Score 2,2 (1.6-2.7) * 0,3(0-1,4)* < 0,001
ESR 57,2 [5-115] ± 25,8 28,6 [2-85] ± 23,5 < 0,001
CRP 24 (12-48) * 11,1 (2-12)* < 0,001
Values are presented as mean or percentage.
* Values are presented as median and quartiles.
Table 3 Comparison of structural damage between baseline and 2 years
Scores Median and inter quartiles
Baseline
N=5 1
Median et inter quartiles
24 months
N=4 5
p
Erosions 0(0-1) 0(0-2) < 0,001
Joint space narrowing 1(0-3) 3(1-8) < 0,001
Total SVDH 1(0-5) 4(1-10) < 0,001
N = patients’ number
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population [19].
At the 2 year assessment, 6 patients (13.6%) have
stopped the DMARD due to socioeconomic difficulties.
Our finding highlights once more another frequent pro-
blem in developing countries inherent to socioeconomic
difficulties encountered in chronic diseases management
[16]. Rkain et al reported that 62% of Moroccan patients
with established RA reported bad observance to treat-
ments because of financial difficulties [4]. In the same way,
an earlier data on therapeutic maintenance of MTX in RA
reported that 14% of Moroccan patients stopped MTX for
socioeconomic reasons [20].
The significant improvement of the disease status
including clinical and biologic parameters is in concor-
dance with the literature findings [21,22].
Practically a third of patients were in remission after this
period whereas there were no patients at baseline. Remis-
sion rates range from 3% to 68% [23] in RA studies
depending on selection of remission criteria, patient selec-
tion, duration of the follow-up period, and therapies.
Our study has provided large information on structural
progression. Forty patients (27.5%) had at least one ero-
sion at baseline. Previous studies have widely demon-
strated that joint damage in RA occurs early in the
disease process [24]. Patients with duration of symptoms
less than 3 months may have already evidence of destruc-
tion [25]. In the ESPOIR cohort, 20% of 813 patients with
mean disease duration of 107 days had hand or foot ero-
sions [26].
Two thirds of our patients did not show any signifi-
cant radiographic progression after 2 years of follow-up.
Comparison of this result with literature is difficult
because of the differences in the study design, patients
and disease features.
Both nonprogressor and progressor patients showed sig-
nificant improvement of clinical and biologic baseline
parameters. Those findings are in line with previous data
showing that radiological progression occurs despite a
clinically and biologically acceptable disease control
[27,28].
Traditional therapy with a single DMARD is often insuf-
ficient to prevent a poor long-term outcome of rheuma-
toid arthritis (RA) [29]. Trials in RA patients have shown
that treatment with combination therapy and/or biologic
agents is more effective in preventing radiographic joint
damage than MTX as monotheray [29-31]. Our progressor
patients would probably benefit strongly from DMARD
combinations or biologic agents.
Many predictor factors of structural progression were
reported in literature [32-35]. According to most of the
published reports, long-term progression of joint damage
was best predicted at baseline by the presence of IgM or
IgA rheumatoid factor, high ESR or CRP level, number of
swollen joints, presence of anti-CCP antibodies, HLA-
DRB1*0401 and 0404 genes, HAQ and early radiographic
erosions. In our study, univariate analysis has initially
shown that the radiographic progression was significantly
associated with three baseline factors: swollen joint
count, total SVDH and Joint space narrowing scores.
However, none of those factors have been retained as
being independent factors of radiologic progression after
multiple logistic regression. This observed lack of asso-
ciation between radiographic progression and different
factors shown in literature could be due to a lack of
power.
Many limitations should be recognized in our study.
First, we recognize that choosing the ACR 1987 classifi-
cation criteria for RA to recruit patients may be criti-
c i z e da n dc o u l db eab i a sr e c r u i t m e n t ,p o s s i b l y
misjudging the baseline structural damage. But at our
study onset, a few years ago, Early arthritis was “ill-
defined": in some studies a disease duration of up to
three years was accepted, whereas other protocols
required a much shorter maximum duration of symp-
toms [36]. In addition, because of technical and financial
considerations, we have not included in the design study
regular assessment throughout the 2 years of follow-up.
T h u s ,w ew e r eu n a b l et oc a l c u l a t et h es c o r eo fr a d i o -
graphic progression. Finally, we should perhaps have
included in database more details on socioeconomic
conditions to analyze their possible contribution to the
course of the disease in our context.
More than a research subject, this study gave us as
clinicians the opportunity to find out the early RA pro-
file in the Moroccan context.
Table 4 Determinant factors of structural progression by
univariate analysis
Items at baseline Radiologic Progression
OR IC 95% P
Age 0.9 (0.92-1.03) 0.4
Sex 0.7 (0.10-4.86) 0.7
Delay in referral to specialist 1 (0.99-1.00) 0.7
Morning stiffness 1 (0.9-1) 0.1
Swollen joint count (0-28) 1.1 (1-1.3) 0.03
DAS 28 1.4 (0.8-2.5) 0.2
HAQ 2.6 (0.8-8.5) 0.1
RF positivity 1.2 (0.3-4.4) 0.8
ESR 1 (0.9-1) 0.1
CRP 1 (0.9-1) 0.3
ACPA 1.7 (0.4-6.3) 0.4
HLA-DRB1*04 1 (0.5-5.7) 0.4
HLA-DRB1*01 2.2 (0.4-12.3) 0.4
Total SVDH score 1.3 (1-1.7) 0.03
Joint space narrowing score 1.4 (1.1-1.9) 0.04
Erosions score 1.8 (0.7-2.7) 0.4
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This study reports, for the first time in Morocco, a devel-
oping African country, a large amount of information
concerning the profile and the course of early RA.
Patients, receiving, for most of them, Methotrexate in
monotherapy and low doses of corticosteroids, showed an
improvement of all clinical and biological disease para-
meters. Moreover, remission was obtained in one third of
patients and two thirds of the cohort had no radiographic
progression at 2 years. No predictor factors of radio-
graphic progression were found out probably in relation
with the small number of patients.
The findings of this study also highlight the difficulties
of early RA in developing countries. The delay in referral
to specialists and interruption of DMARD due to financial
difficulties are the most important problems encountered
in our context.
The small size of our sample and the absence of regular
monitoring of clinical, biological and radiographical para-
meters during the course of the disease are the most
important limitations of our study.
The best way to investigate the course of early RA in
the Moroccan population would be through a prospective
longitudinal study, following an unbiased cohort of
patients with early RA with regular clinical, biological
and radiographical assessments for many years. Such
multicentric inception cohort of early arthritis with a lar-
ger sample will give more precious informations about
early RA characteristics and course and will constitute a
major keystone in the management of this disabling dis-
ease in our country. Such a prospective study is already
ongoing in Morocco.
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